Skip to content
Nikang Therapeutics
About Us
Science & Pipeline
News
Careers
Home
About us
Science & Pipeline
News
Careers
NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression
See the press release on
Business Wire